Page 107 - HIV/AIDS Guidelines

2007;23(12):1505-1514.

4. Stone VE, Jordan J, Tolson J, et al. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral
therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART)
regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36(3):808-816.
5. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy
in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen:
the SWAN Study (AI424-097) 48-week results. Clin Infect Dis. 2007;44(11):1484-1492.
6. Squires KE, Young B, Dejesus E, et al. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir,
each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in
HIV-infected patients. AIDS. 2010;24(13):2019-2027.
7. Martinez E. The NEFA study: results at three years. AIDS Rev. 2007;9(1):62.
8. Ochoa de Echaguen A, Arnedo M, Xercavins M, et al. Genotypic and phenotypic resistance patterns at virological failure
in a simplification trial with nevirapine, efavirenz or abacavir. AIDS. 2005;19(13):1385-1391.
9. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-
based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre,
double-blind, randomised controlled trials. Lancet. 2010;375(9712):396-407.
10. Vispo E, Barreiro P, Maida I, et al. Simplification From Protease Inhibitors to Once- or Twice-Daily Raltegravir: The
ODIS Trial. HIV Clin Trials. 2010;11(4):197-204.

11. Martinez E, Larrousse M, Llibre JM, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-
infected patients: the SPIRAL study. AIDS. 2010;24(11):1697-1707.

12. Harris M, Larsen G, Montaner JS. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir
within a virologically suppressive regimen. AIDS. 2008;22(10):1224-1226.

13. De Castro N, Braun J, Charreau I, et al. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-
resistant HIV-1-infected patients: a randomized open-label trial. Clin Infect Dis. 2009;49(8):1259-1267.

14. Harris M, Larsen G, Montaner JS. Exacerbation of depression associated with starting raltegravir: a report of four cases.
AIDS. 2008;22(14):1890-1892.
15. Loutfy M, Ribera E, Florence E, et al. Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in
the early access programme. J Antimicrob Chemother. 2009;64(6):1341-1344.
16. Havlir DV, Marschner IC, Hirsch MS, et al. Maintenance antiretroviral therapies in HIV infected patients with
undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med.
1998;339(18):1261-1268.
17. Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance
antiretroviral therapy after sustained virologic suppression. JAMA. 2006;296(7):806-814.
18. Pulido F, Arribas JR, Delgado R, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides
for maintenance therapy of HIV. AIDS. 2008;22(2):F1-9.
19. Arribas JR, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for
patients with HIV RNA below 50 copies/ml. AIDS. 2010;24(2):223-230.
20. Katlama C, Valantin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients
with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS.
2010;24(15):2365-2374.

21. Delfraissy JF, Flandre P, Delaugerre C, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in
antiretroviral-naive HIV-infected patients. AIDS. 2008;22(3):385-393.

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents H-14

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.